title: [Performance evaluation of integrated cytoprotective therapy of different duration in patients with cerebral infarction].
abstract: The paper reviews the preliminary results of a multicenter randomized clinical research. The aim of the study was to determine the optimal duration of different types of energy-correction therapy. 99 case report forms of patients with cerebral infarction were reviewed with their prior envelope randomization into three groups. Patients in the first group (experimental group), consisting of 32 patients, as part of combined therapy received ascorbic acid (5% solution twice a day in a recommended dosage of 20 ml/day for 20 days); the second group (37 patients) received 10 ml of cytoflavin intravenously by drop infusion twice a day for 10 days; the third group received cytoflavin for 20 days (from day 1 to day 10 - 20 ml a day, from day 11 to day 20 - 10 ml a day). The average NIH scale score on admission was 14.9 ± 2.6. Prescription of cytoflavin came with average 1.7 - 1.8 time regression (p < 0.05) of the volumes of cerebral ischemia in the of cases of the 10- and 20-day courses of treatment, while there were no significant morphologic changes in the ascorbic acid group. These results correlated with the best dynamics and outcomes of the neurological and performance status of patients receiving cytoflavin. Despite the lack of significant general differences in the clinical and morphological data of the second and third groups, the patients with underlying grave medical condition in the 20-day cytoflavin group (with NIH score of 14-20 points on admission) tended to have improved neurologic status parameters in comparison with the experimental group and the 10-day cytoflavin group. These results attest to the advantages of personalized antioxidant energy-correction therapy.
authors.forename: L V
authors.initials: LV
authors.lastname: Chichanovskaia
authors.forename: L A
authors.initials: LA
authors.lastname: Tsukurova
authors.forename: A L
authors.initials: AL
authors.lastname: Kovalenko
authors.forename: M V
authors.initials: MV
authors.lastname: Nazarov
authors.forename: D I
authors.initials: DI
authors.lastname: Lukin
authors.forename: S A
authors.initials: SA
authors.lastname: Rumiantseva
authors.forename: E V
authors.initials: EV
authors.lastname: Silina
authors.forename: V A
authors.initials: VA
authors.lastname: Stupin
authors.forename: T Iu
authors.initials: TIu
authors.lastname: Nedorostkova
authors.forename: E N
authors.initials: EN
authors.lastname: Kabaeva
authors.forename: E V
authors.initials: EV
authors.lastname: Eliseev
mesh_terms: D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use*; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003071:Cognition / Q000187:drug effects; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D006801:Humans; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000627:therapeutic use*; D057285:Precision Medicine; D011581:Psychological Tests; D012426:Russia; D012720:Severity of Illness Index; D013386:Succinates / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate; D001205:Ascorbic Acid